Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy

作者：Qi Yao, Jia Wang, Jingyi Li, Qi Deng · 发表于：Cancer Biology and Medicine · 年份：2025 · DOI：10.20892/j.issn.2095-3941.2025.0087 · 被引用次数：2 · 研究领域：CNS Lymphoma Diagnosis and Treatment、Chronic Lymphocytic Leukemia Research、Immune Cell Function and Interaction

Because human immunodeficiency virus (HIV)-associated Burkitt lymphoma (BL) has a poor prognosis new therapeutic approaches need to be developed[1][1]. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR-T cell commercially available FDA-approved product for patients with relapsed or refractory (R